The Miniature American Shepherd faces two health challenges that deserve every owner's attention: a genetic mutation affecting tolerance to certain medications, and an articular predisposition inherited from its ancestors.

Both of these realities are manageable, provided they are known.

The Miniature American Shepherd (MAS) in brief

Appeared in the 1960s in California, the MAS originated from the selection of the smallest specimens of the Australian Shepherd. (in the photo, it is on the left)

The goal: to retain working qualities in a size suitable for city living. Recognized by the AKC in 2015 in the Herding group.

MDR1 mutation: what every owner needs to know

What is the MDR1 (ABCB1) mutation?

The ABCB1 gene, historically called MDR1, codes for a membrane protein: P-glycoprotein (P-gp).

This protein actively expels certain molecules from cells, particularly at the blood-brain barrier.

In the absence of functional P-gp, some drugs normally excluded from the brain accumulate there, with potentially serious consequences: tremors, ataxia, seizures, coma, death.

The molecular basis was identified in 2001: a 4 base pair deletion in the ABCB1 gene (c.227_230delATAG) causes a premature stop codon and the production of a truncated non-functional P-gp ( Mealey et al., 2001 - PMID 11692082 ).

Prevalence in MAS

A European study of 4,729 dogs of predisposed breeds documented a mutated allele frequency of 26.1% in the European Miniature Australian Shepherd, comparable to MAS ( Firdova et al., 2016 - PMID 27234542 ).

Important point : there is currently no dedicated PubMed study evaluating this frequency specifically in the Miniature American Shepherd recognized by the AKC since 2015. Available data come from the European Miniature Australian Shepherd and genotyping laboratories. Caution is advised upon acquisition, modifying the absence of precise data.

Mode of transmission: incomplete dominance

Documented case : a heterozygous dog that received cyclosporine at standard dose showed unexpected excessive immunosuppression, despite plasma concentrations within usual targets ( Mackin et al., J Am Anim Hosp Assoc 2020 - PMID 32182109).

Affected medications

Source: Mealey KL, Owens JG, Freeman E. (2023) - J Vet Pharmacol Ther 46:1-16. PMID 36326478

Genetic Testing: Why and How

MDR1 genotyping is available from several accredited laboratories (Washington State University VGL, Antagene in France, Laboklin).

It is performed using a buccal swab or blood sample.

The result is permanent and should be recorded in the dog's health record, to be communicated to any veterinarian during consultations.

For breeders, genotyping breeding dogs helps to progressively reduce allele frequency: by breeding double-mutant x double-mutant dogs, the risk of producing homozygous puppies, who are the most vulnerable, is eliminated.

Joint Health: Dysplasia and Daily Comfort

What We Know

The Miniature Australian Shepherd (BAM) shares part of its genetic background with the Australian Shepherd, a breed in which joint dysplasias are documented.

To date, there are no PubMed studies specifically evaluating the prevalence of dysplasias in the BAM: the breed is young (recognized by the AKC in 2015) and the numbers in orthopedic databases remain limited.

Available data comes mainly from the OFA registry, whose submissions are voluntary and biased towards healthy dogs.

What is established : its active morphology, high energy level, and physical demands associated with canine sports make it a candidate to monitor from a young age.

The three dysplasias to be aware of

Sources: Oberbauer AM et al. (2017) - PLoS One, PMID 28234985 / OFA Breed Statistics

Hip Dysplasia

Abnormal joint development creates repeated microtrauma, progressively leading to osteoarthritis.

The first signs sometimes appear as early as 6 months in severe forms, but often later: morning stiffness, reluctance to jump, waddling gait.

Diagnosis relies on radiographs under sedation.

Two methods: OFA (read by three accredited radiologists, from 24 months) and PennHIP (measurement of joint laxity by distraction, possible from 16 weeks, with better predictive value according to literature).

Elbow Dysplasia

It encompasses several conditions (ununited anconeal process, fragmented medial coronoid process, osteochondrosis of the medial humeral condyle) and typically manifests between 4 and 12 months of age with lameness in one or both front limbs. Excessive intensive exercise before the growth plates close (around 12 to 14 months) is a recognized aggravating factor.

Patellar Luxation

More common in small breeds.

The kneecap displaces medially (inward) or, more rarely, laterally.

The classic sign is a skipping gait or intermittent lameness.

Some dogs adapt so well that they show no signs despite obvious grade 1 or 2 luxation.

Multimodal Management

The management of osteoarthritis relies on a combined approach. A review published in 2024 in the Journal of Small Animal Practice (PMID 37776028) lists non-pharmacological therapies with documented efficacy.

Weight Control

Overweight is the most well-documented modifying factor.

A weight reduction of 6 to 18% objectively improves gait, as measured by kinetic analysis, and reduces pain scores.

The Miniature Australian Shepherd tends to eat well: controlling energy intake is a preventive priority.

Exercise

Immobility aggravates osteoarthritis.

Regular, moderate, low-impact exercise (leash walking, swimming, hydrotherapy) maintains muscle trophic health, lubricates cartilage, and preserves joint range of motion. High-impact activities (repeated jumping, intense agility) should be managed, especially before growth plates have fused.

Thermotherapy

Gentle heat applied to a chronically inflamed joint increases local blood circulation, reduces muscle stiffness, and improves the extensibility of periarticular tissues.

Applicable at home in addition to veterinary treatments.

Nutraceuticals

Omega-3 fatty acids (marine-derived EPA/DHA) are the most well-documented for canine osteoarthritis: several randomized controlled studies show a significant improvement in lameness scores.

NSAIDs remain the gold standard for acute pain, but nutraceuticals have a place in long-term management.

Other ingredients (hydrolyzed collagen, eggshell membrane, MSM, green-lipped mussel extracts) are the subject of preliminary work, with a current level of evidence lower than that of omega-3s.

Two predispositions to reconcile

The MDR1 mutation does not prevent it from being treated; it simply requires that each treatment is selected with knowledge of its genetic status.

The joint predisposition does not condemn it to a sedentary lifestyle; it calls for particular attention during growth, preventive radiographic monitoring in breeding animals, and an adapted living environment.

What you can do:

• Have your BAM tested as early as possible, ideally upon acquisition, before any risky prescriptions (antiparasitics, anesthetics, immunomodulators, anticancer drugs).

• Exclusively inform the veterinarian of the MDR1 status before any prescription of antiparasitic, anesthetic, or anticancer medications.

• Avoid high doses of certain macrocyclic lactones in non-genotyped dogs, as a precautionary measure.

• Have breeding dogs' hips and elbows X-rayed, ideally between 18 and 24 months.

• Limit high-impact exercises before 14 months to protect developing cartilage.

• Maintain a balanced diet and a healthy weight throughout life.

• In case of signs of stiffness or joint pain, consult quickly rather than waiting: the earlier the care, the more effective conservative options are.

________________________________________________________________________________________________

Sources